Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, Senan S. Radiother. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Quality of life. Experiences of case managers in providing. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Treatment of stage I NSCLC in elderly patients: a. Kumar,. ; (2), KIM MS et al. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). J Thorac Oncol. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. Slotman BJ, van Tinteren H, Praag JO, et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Stereotactic Slotman B, Senan S.